Neoadjuvant/chemo nivolumab wins EU approval for resectable PD-L1+ NSCLC

Neoadjuvant/chemo nivolumab wins EU approval for resectable PD-L1+ NSCLC

The European Commission (EC) has approved nivolumab (Opdivo) in combination with platinum-based chemotherapy for the neoadjuvant treatment of patients with resectable non-small cell lung cancer (NSCLC) at high risk of recurrence with PD-L1 expression in cells tumors of at least 1%.1 The regulatory decision was supported by data from the Phase 3 CheckMate 816 study … Read more

Muscular Dystrophy Association Celebrates FDA Approval of Sarepta Therapeutics’ ELEVIDYS for Treatment of Duchenne Muscular Dystrophy | Muscular Dystrophy Association

Image of a DNA strand with the words, Breaking News, New FDA Drug Approval for Duchenne Muscular Dystrophy (DMD).  The first gene therapy for DMD.

Muscular Dystrophy Association Celebrates FDA Approval of Sarepta Therapeutics’ ELEVIDYS for Treatment of Duchenne Muscular Dystrophy The FDA approval of the first gene therapy for Duchenne muscular dystrophy (DMD) by Sarepta Therapeutics is groundbreaking and designed to target the underlying cause of the disease. The Muscular Dystrophy Association (MDA) has been around since the inception … Read more